Jupiter Neurosciences Publishes Shareholder Letter, Outlines 2026 Outlook

Jupiter Neurosciences announced the publication of a shareholder letter from Chairman and CEO Christer Rosen marking Jupiter's first full year as a public company and outlining the major achievements and strategic priorities propelling the Company into 2026. The letter read, in part, "As we celebrate our first full year as a public company, I want to express my deepest gratitude for your belief in Jupiter Neurosciences and the mission we are pursuing. When we completed our IPO in December 2024, we did more than enter the public markets - we stepped into a new era defined by bold ambition, scientific conviction, and the unwavering pursuit of improving human healthspan and longevity. Over the course of 2025, Jupiter laid a powerful foundation for long-term value creation, executed on every major initiative we committed to, and opened the door to a year of extraordinary opportunity ahead...As we enter 2026, Jupiter is positioned for one of the most important years in our company's history. Launch and enrollment of the Phase 2a Parkinson's trial, with initial biomarker insights anticipated as the study progresses. First full year of Nugevia revenue, with subscription growth driving predictable, high-margin cash flow. Expansion of global distribution, licensing, and longevity partnerships, particularly within Asia. Strengthening our position for future profitability, supported by the dual-engine business model validated in 2025. Acceleration of ongoing research into GLP-1 synergies, metabolic inflammation, and neuroprotective mechanisms - areas where JOTROL continues to show compelling potential."